HUTCHMED (NASDAQ:HCM) Shares Gap Up – Here’s What Happened

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM)’s share price gapped up prior to trading on Friday . The stock had previously closed at $15.31, but opened at $16.00. HUTCHMED shares last traded at $16.11, with a volume of 35,560 shares changing hands.

Wall Street Analysts Forecast Growth

Several research firms have commented on HCM. Morgan Stanley cut HUTCHMED from an “equal weight” rating to an “underweight” rating and lowered their price target for the company from $18.00 to $13.75 in a report on Monday, September 22nd. Wall Street Zen upgraded shares of HUTCHMED from a “hold” rating to a “buy” rating in a report on Sunday, November 16th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of HUTCHMED in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, HUTCHMED currently has an average rating of “Hold” and a consensus price target of $20.88.

HUTCHMED Price Performance

The stock has a fifty day moving average price of $14.14 and a 200-day moving average price of $15.42. The company has a current ratio of 4.65, a quick ratio of 4.51 and a debt-to-equity ratio of 0.05.

Institutional Investors Weigh In On HUTCHMED

Several large investors have recently made changes to their positions in the business. Blue Trust Inc. lifted its holdings in shares of HUTCHMED by 131.5% during the 4th quarter. Blue Trust Inc. now owns 7,708 shares of the company’s stock valued at $103,000 after acquiring an additional 4,378 shares in the last quarter. Vanguard Personalized Indexing Management LLC raised its position in HUTCHMED by 23.2% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 15,490 shares of the company’s stock valued at $233,000 after purchasing an additional 2,916 shares during the period. Ameriprise Financial Inc. lifted its stake in shares of HUTCHMED by 4.7% during the second quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock worth $234,000 after purchasing an additional 698 shares in the last quarter. Bank of America Corp DE lifted its stake in shares of HUTCHMED by 17.3% during the second quarter. Bank of America Corp DE now owns 20,582 shares of the company’s stock worth $310,000 after purchasing an additional 3,035 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of HUTCHMED by 34.2% in the third quarter. Dimensional Fund Advisors LP now owns 21,721 shares of the company’s stock worth $342,000 after buying an additional 5,538 shares during the period. Institutional investors and hedge funds own 8.82% of the company’s stock.

About HUTCHMED

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.